Duerr M, et al. - In this prospective single-center trial, researchers assessed the efficacy and safety of daclatasvir (DCV) and sofosbuvir (SOF) over 12 weeks in 16 adult chronic hepatitis C virus (HCV) infected kidney transplant recipients (KTR) and eGFR > 30 ml/min/1.73m². Sustained virological response 12 weeks after end of therapy (SVR12) was assessed as the primary endpoint. Regular evaluation of beside baseline liver biopsy, hepatic function and glucose metabolism was also carried out. Previously failed interferon-based HCV treatment was reported in 4 patients. SVR12 was achieved by 15 of 16 KTR. SVR12 achievement was also observed in association with rescue treatment with SOF/velpatasvir/voxilaprevir. Significant improvement of liver metabolism and glucose tolerance was noted in association with direct-acting antiviral agents (DAAs) treatment, with no therapy-associated major adverse events and excellent tolerability. Overall, DCV/SOF treatment proved to be safe as well as efficacious and offered a functional benefit for KTR with chronic HCV infection.